Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole add-on to methylphenidate for children with ADHD
IRCT20100520003979N7Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing Pramipexole + methylphenidate with Placebo + methylphenidate (2 arms). Primary endpoint: Attention deficit hyperactivity score at 12 weeks. Started May 2018; status: completed.
02
Drugs
pramipexolemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on IRCT20100520003979N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20100520003979N7.